Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Table 1 Characteristics of the UPREAL-PsA study patients at baseline

PsA Patients	Total number (%)
Gender, female	86 (68.3)
Gender, male	40 (31.7)
Age, years ± SD	56.5 ± 11.4
BMI, value ± SD	26.7 ± 5.1
Cardiovascular Diseases^a	40 (31.8)
Hypertension	27 (21.4)
Metabolic Diseases^b	32 (25.4)
Obesity	23 (18.3)
Diabetes type II	12 (9.5)
Depression/Anxiety Disorder	18 (14.3)
Neoplastic Diseases^c	7 (5.6)
Other Comorbidities^d	98 (77.8)
Peripheral PsA	124 (98.4)
Axial PsA	54 (42.9)
Enthesitis	69 (54.8)
Dactylitis	30 (23.8)
Skin	78 (61.9)
Nails	44 (34.9)
Uveitis (ever)	6 (4.8)
IBD (ever)	6 (4.8)
DAPSA at baseline, mean ± SD	27.7 ± 10.0
ASDAS-CRP at baseline^e, mean ± SD	2.65 ± 0.69
Disease Duration, months median (IQR)	92 (45–177)

Clinical features of patients’ cohort in UPREAL-PsA (Upadacitinib therapy in the real-life in patients with psoriatic arthritis)
PsA Psoriatic Arthritis, PsO Psoriasis, BMI Body Mass Index, Oligo Oligoarticular involvement, Poly Polyarticular Involvement, IBD Inflammatory Bowel Disease, DAPSA Disease Activity in Psoriatic Arthritis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score with the C-reactive protein, SD Standard Deviation, IQR Interquartile Range
^aIschemic Cardiomyopathy, Heart Failure, Cardiac Arrhythmias (any), valvular disease (any), Stroke, Venous Thromboembolism, Pericardial Disease, other Cardiomyopathies
^bDiabetes type I, Dyslipidaemia, Osteoporosis
^cSolid Cancer. Haematological Cancer, Non-Melanoma Skin Cancer
^dSee Additional Table 2
^eOnly in patients with axial PsA (n = 54)

ISSN: 1478-6362